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Abstract 
Background: Ligand binding thermodynamics has been attracted considerable interest in the past 
decade owing to the recognized relation between binding thermodynamic profile and the 
physicochemical and druglike properties of compounds. Discussion: • Affinity improvements in drug 
discovery optimizations can be either enthalpically or entropically driven. In this review the relation 
between optimization strategies and ligand properties are presented based on the structural and 
thermodynamic analysis of ligand-protein complex formation. Conclusions: The control of the 
binding thermodynamic profile is beneficial for the balanced affinity and physicochemical properties 
of drug candidates and early phase optimization gives more opportunity to this control. 
 
Drug discovery optimizations and molecular obesity 
The objective of drug discovery projects at the preclinical stage is to find compounds with balanced 
properties that include high affinity towards the target, sufficient specificity and selectivity and 
advantageous physicochemical and pharmacokinetic profile. The evolution of the chemical starting 
point to a clinical candidate is a result of a multiparametric optimization process. While increasing 
the binding affinity is of primary importance in early optimizations the monitoring and improvement 
of other druglike properties are also part of the optimization process from the outset and they 
become even dominant with the advance of the optimization. It is well documented [1,2,3] that 
affinity improvement tends to increase molecular size and lipophilicity, leading to large, hydrophobic  
compounds, a phenomenon called molecular obesity [4,5]. This type of compound has a greater 
chance being promiscuous [2,6,7], having low solubility and suboptimal ADMET properties [8]. 
Therefore, it is of utmost importance to understand the relationship among the various properties to 
be optimized simultaneously and it has been increasingly recognized that binding thermodynamics 
(Box 1) may serve as a link among these properties. In addition to its obvious relationship to binding 
affinity binding thermodynamics impacts other important druglike parameters such as the 
physicochemical profile, binding selectivity, specificity and promiscuity. It has been demonstrated 
that enthalpic compunds have typically better profile of physicochemical parameters than that of the 
high entropy compounds [9]. Freire and coworkers showed that enthalpic compounds have higher 
chance being selective against off-targets [10]. Compounds binding their targets with higher entropy 
contributions tend to hit more off-targets compared to those ligands that had enthalpically-driven 
thermodynamics profile [11]. Thermodynamic investigations might therefore help both in the 
understanding of interconnecting relations between molecular properties and also in controlling 
them. 
Affinity optimization is typically realized by introducing new atoms in the molecule. This process is 
validated by the observation that the available maximal affinity of ligands toward protein targets 
increases with increasing ligand size as it was first observed by Kuntz et al. [12] and later for a larger 
data set by Reynolds et al. [13]. The same trend was also identified using affinities from 
thermodynamic measurements [14]. This already indicates that care has to be taken in affinity 
improvements in order to avoid excessive size and lipophilicity increase. At this point, it is 
appropriate to analyze ligand-protein interactions and the process of complex formation to 
understand the detailed relationship between ligand size and affinity. 
Ligand-protein binding is a complex, multistep process that includes the desolvation of the partners, 
their conformational change and the formation of new interactions between them. An important 
component of the process is the reorganization of water networks as a consequence of the release of 
water molecules from the solvation shells of the binding partners. All these steps contribute to the 
enthalpy and entropy changes that accompany binding and both contributions are affected by the 
structure of the ligand and the way it binds to the protein. The increasing amount of structural and 
thermodynamic data makes it possible to analyze how the interactions and the thermodynamic 
profile depend on various quantities like ligand size, lipophilicity and affinity. This, in turn, allows us 
better understanding of the evolution of these latter quantities in the course of optimization. 
 
 Size-dependence of ligand-protein interactions 
The interaction of fitting polar groups of the ligand and the protein is potentially highly beneficial and 
can significantly contribute to the binding free-energy primarily by enthalpic gain [15]. The formation 
of polar interactions, however, is accompanied by unfavorable contributions that come from the 
desolvation of the polar groups and the decreased mobility of the interacting moieties. These 
predominantly entropic unfavorable contributions can only be compensated by the enthalpy gain of 
polar interactions if the geometrical arrangement of atoms is near to optimal. H-bonds are probably 
the most important polar interactions and their energy is highly sensitive to the relative positions of 
the participating atoms. An analysis of the optimal geometry H-bonds (donor-acceptor distance not 
larger than 3 Å and D-H…A angle is not smaller than 160 °) in ligand-protein complexes of the Protein 
Data Bank [16] revealed [17] that the average number of such H-bonds is around two even for small 
molecules having ~15 heavy atoms and the average number does not increase significantly with 
increasing ligand size. The appearance of optimal geometry H-bonds in complexes of small molecules 
is in line with the high free-energy gain associated with these H-bonds. Their number, however, does 
not increase for larger ligands and this finding can be rationalized by the high sensitivity of the H-
bonding energy to the geometry of the interacting atoms that prevents the formation of further 
optimal geometry H-bonds that could beneficially contribute to the binding free-energy. Larger 
molecules, however, are able to bind with larger free-energy gain as it was discussed above, thus 
they have to find another way to achieve high affinity. Apolar desolvation appears to be able to 
contribute favorably to the binding of large molecules. Indeed, correlation was found between the 
apolar surface area buried upon complex formation and the binding free-energy [18], and their 
relation suggests 1 kJ/mol free-energy gain upon the burial of 20 Å2. The apolar surface area and the 
corresponding estimated binding free-energy was calculated for ligands in the Protein Data Bank and 
they are depicted as a function of heavy atom count in Figure 1. The amount of free-energy coming 
from apolar desolvation for a molecule of 20 heavy atoms is at most 15 kJ/mol according to Figure 1 
and it corresponds to the lower limit of the estimated entropy loss upon binding [19]. This suggests 
that apolar desolvation alone is unable to ensure the binding of small molecules. However, it 
becomes increasingly important as molecular size increases. Since polar interactions are unable to 
increase their favorable contribution to binding (see above) it is apolar desolvation that becomes the 
driving force of ligand-protein binding in the case of large ligands. 
 Size-dependence of ligand-protein binding thermodynamics 
As it was discussed above, polar interactions are able to contribute to binding primarily by enthalpic 
gain while the contribution of apolar desolvation is dominantly entropic. Then the involvement of 
these effects in the formation of ligand-protein complexes has to be reflected in the thermodynamic 
profile of the binding. Plotting the average enthalpic and entropic contributions to binding free 
energy as a function of ligand size (Figure 2) shows the expected trend. Enthalpy dominates for 
smaller ligands [14,20] in line with the importance of polar interactions for these molecules and 
entropy becomes dominant for large molecules as a consequence of the increased contribution of 
apolar desolvation. 
The desolvation contribution to binding is related to the surface area as it is supported by the 
correlation between buried apolar surface area and the binding free-energy [18] and also by a model 
that includes apolar surface area to calculate binding enthalpy [21]. Detailed thermodynamic and 
structural analyses of the water network and its perturbation by ligands can distinguish water 
molecules whose repulsion from the binding site is favorable or unfavorable in terms of their 
contribution to binding free energy and its components [22,23,24,25,26]. Although an assignment of 
free-energy and its components to water molecules is an approximation it contributes to our 
understanding of the role of water in ligand binding. It appears that the enthalpic component of 
water repulsion can be both favorable and unfavorable while the entropic component is basically 
favorable [26,27,28]. This finding is in agreement with the increasing role of entropy gain for larger 
ligands. 
The trend of decreasing enthalpic contribution with increasing ligand size is also observed for the 
highest affinity compounds. While available affinity increases with ligand size the corresponding 
enthalpic contribution diminishes for large ligands as it is shown in Figure 3. This plot was generated 
by assigning the compounds to bins defined by heavy atom counts and the highest pKd is shown for 
each bin together with the maximal pKH of those compounds of the bin whose affinity is in the top 
5% (most enthalpic binders among the top affinity compounds). It appears that small size high 
affinity compounds are able to bind with favorable enthalpy while the contribution of enthalpy 
diminishes with increasing ligand size. Large ligands are able to bind with higher affinity by higher 
entropic contribution. 
 
Optimization strategies and binding thermodynamics 
The basic challenge in affinity improvement from thermodynamics point of view is to overwrite 
enthalpy-entropy compensation [29]. Optimizations can then be classified as enthalpically and 
entropically driven; enthalpically driven optimizations achieve this goal by dominantly pKH increase, 
while pKS increase dominates in entropically driven optimizations. Since pKH can be improved by the 
introduction of new polar interactions, enthalpically driven optimizations have the advantage to 
produce improved affinity compounds with balanced physicochemical properties and advantageous 
pharmacokinetic profile. However, designing new beneficial polar interactions is difficult that makes 
enthalpically driven optimization challenging [15]. By contrast, entropically driven optimizations 
increase affinity by improving pKS. This can be achieved by introducing apolar groups into the ligand 
so that they match the protein binding site and thus primarily increasing favorable entropy by 
desolvation. Another way to increase pKS is to reduce ligand flexibility typically achieved by applying 
chain-ring strategies leading to larger, more complex molecules. Both lipophilicity and complexity 
increase is generally more straightforward than the design of new beneficial polar interactions and 
thus entropically driven optimizations are easier to realize. However, entropy dominated 
optimizations are coupled with extensive increase in molecular size and lipophilicity as it is shown by 
the comparison of these parameters for enthalpy and entropy dominated binders [14,9] and these 
features adversely affect physicochemical properties and pharmacokinetic profiles (see e.g. refs 1 
and 3). 
Enthalpically driven optimization is preferred over entropically driven optimization, although, as 
argued above, it is far more difficult to pursue. Moreover, enthalpically driven optimization appears 
to be more feasible for smaller compounds as it is shown in Figure 2 and Figure 3. This suggests that 
increasing the enthalpy content of binding is effective in the early stages of the optimization and 
furthermore that enthalpic starting points are beneficial. Measuring and comparing the binding 
enthalpy of ligands at decision points like hit and lead selection and monitoring the enthalpy in early 
optimizations is expected to advantageously affect the quality of optimized compounds. Late stage 
optimizations often improve potency at the expense of increased binding entropy and tend to 
produce more complex and more lipophilic compounds. This is illustrated in Figure 4 that shows the 
average binding enthalpy and entropy as a function of affinity. Low affinity compounds bind 
enthalpically and the entropic contribution on average is near to zero. The majority of these low 
affinity compounds are fragments containing not more than 22 heavy atoms and these small polar 
compounds bind enthalpically as it is discussed later. On the other hand, the thermodynamic profile 
above pKd=8 starts to be seriously biased towards entropy and this suggests that affinity increase in 
that range threaten the quality of physicochemical properties and pharmacokinetic profile. 
 Thermodynamic rationale of fragment based approaches 
The chemical starting points of fragment-based drug discovery programs are small, low complexity, 
polar compounds with typically low affinity. Owing to their low affinity, compounds have to be 
screened at high concentration that requires high solubility. In line with their small size and polarity 
that allows fragments to form few, good quality polar interactions without significant contribution 
from apolar desolvation fragment hits typically bind with favorable enthalpy [17,30,31,32,33,34,35] 
(Figure 5). The few compounds in Figure 5 that bind with unfavorable enthalpy are all anionic species 
with highly unfavourable desolvation profile. Another factor that affects binding thermodynamics is 
the rigid body entropy loss that is estimated to be 15-20 kJ/mol [19] and fragments are able to 
compensate this entropy loss at a lesser extent than larger compounds. It is worth also noting that 
the perturbation of the water network upon binding although associated with significant 
contribution to binding thermodynamics [36,37] is less important for fragments than for larger size 
ligands. Summarizing, fragments have a binding thermodynamic profile characterized by enthalpy 
domination and this, first, distinguishes them from larger ligands and, second, forms the 
thermodynamic rationale of fragment based approaches. Fragments are highly appropriate starting 
points of drug discovery programs as they have already important polar interactions formed with the 
hot spot of the protein [17] and due to their enthalpic character provide large operational freedom 
for a balanced optimization. 
 
Ligand efficiency indices and binding thermodynamics 
 Ligand efficiency and enthalpic efficiency 
Drug discovery optimizations face the challenge of simultaneously improving affinity, selectivity, 
physicochemical properties and pharmacokinetic profile. Both decision points like hit and lead 
selection and the optimization process require the complex characterization of compounds in order 
to compare them. Ligand efficiency indices are appropriate tools for such characterizations since they 
are composite measures that carry complex information, yet they can be easily obtained. Various 
efficiency indices have been proposed (Table 1) some of them are more widely accepted and used 
than others [38,39,40].The most widely used index is ligand efficiency (LE) that expresses the ratio of 
affinity and ligand size. It was originally defined as  [41] although pKd, pKI and pIC50 are often 
used instead of G (Table 1). It has to be recognized that although LE is the affinity normalized to the 
number of atoms, its maximal available value does depend on ligand size [13] and this fact biases the 
comparison of different size ligands. This recognition led to the definition of size-independent ligand 
efficiency, , whose maximum available value is independent of ligand size [43]. 
Indeed, it was demonstrated [44] that LE does not exhibit a clear trend in optimizations, while SILE 
shows a significant increase in successful optimizations and thus it is an effective tool in hit and lead 
selection and also in monitoring optimizations. 
The enthalpy content of binding contains information about the type and quality of ligand-protein 
interaction and this prompted the definition of enthalpic efficiency , where Q is either the 
number of heavy atoms or the molecular mass [30,45]. An alternative index is specific  that 
measures the enthalpy change relative to the number of polar atoms [30]. The maximal available 
value of both enthalpic efficiency and specific enthalpic efficiency heavily depend on ligand size and a 
size-independent version, , was defined [14] for the unbiased comparison of the 
binding enthalpy content of different sized ligands. Although the available enthalpy may be target 
dependent it does not affect compound comparison based on SIHE values against the same target as 
it is typically required in drug discovery optimizations. However, the maximal available binding 
enthalpy does not change monotonically with ligand size (Supplementary Figure S1) and therefore 
neither EE nor SIHE is appropriate to compare very small compounds against those having more than 
15 heavy atoms. It has to be also noted that a division by the number of heavy atoms have a damping 
effect and thus both LE and EE cover a decreasing range with increasing heavy atom count. This has 
the consequence that LE and EE contain less information for large compounds, but size-independent 
measures, like SILE and SIHE, do not suffer from this deficiency as their definition ensures ligand size 
independent maximal values (Supplementary Figure S2). This difference between the size dependent 
and size independent measures is apparent already around the fragment limit of 22 heavy atoms. 
The calculation of ligand efficiency requires the knowledge of affinity, and the calculation of 
enthalpic efficiency requires the knowledge of enthalpy. While affinity measurements are part of the 
standard drug discovery setup thermodynamic measurements are less common and this currently 
restricts the use of enthalpic indices. It is worth also noting that the decreasing trend of maximal 
available ligand efficiency (Supplementary Figure S2c) resembles to the trend observed for enthalpic 
efficiency. The maximal available enthalpy decreases with ligand size [17] and so does the maximal 
enthalpic efficiency [20]. Since this decrease is not fully compensated by an entropic efficiency 
increase the maximal available ligand efficiency decreases. 
 
 Lipophilic efficiency 
Lipophicity is an important property of ligands as it affects affinity, selectivity and ADMET properties. 
Lipophilicity tends to increase in entropically driven drug discovery optimizations and its 
thermodynamic background was discussed above. Selectivity and specificity typically decrease with 
increasing lipophilicity [2], while the relationship between lipophilicity and ADMET properties is more 
complex. Less lipophilic compounds tend be more soluble [46], less impacted by liver metabolism 
and hepatic clearance [47], and less toxic [48]. On the other hand, however, they show low 
permeability across biological membranes [49] and highly affected by renal clearance [50]. These 
observations suggest that lipophilicity has an optimal range to achieve during drug discovery 
optimizations and this is also supported by the analysis of discovery datasets that identified optimal 
lipophilicity ranges for oral drugs between 0.8 and 3.2 logP units [51] and between 2 and 3.2 logP 
units [9]. 
The narrow range of optimal lipophilicity has serious consequences on both the identification of 
chemical starting points and on their optimization. Lipophilic indices are designed to control the 
balance with respect to the lipophilicity and other properties like affinity and size. Definitions of 
commonly used lipophilic indices are shown in Table 1. 
Ligand lipophilicity efficiency (LLE), historically the first lipophilic index, was proposed to have target 
values ~5-7 or larger [2]. These values were recommended on the basis of the clogP~2.5 and potency 
range~1-10 nM taken as average values for oral drugs. Compounds at hit identification and early 
optimizations typically do not achieve this LLE range and other lipophilic indices that also include 
ligand size were proposed. Lipophilicity corrected ligand efficiency (LELP) [1] describes the price of 
ligand efficiency paid in logP. The target values for LELP were proposed to be between -10 and +10 
based on the widely accepted lower limit of ligand efficiency (0.3), and on the lipophilicity range 
between –3 and +3. LLEAT was proposed to characterize small screening hits, like fragments and it is 
defined to have a target value (0.3) and dynamic range similar to ligand efficiency (LE) [52]. 
Lipophilic indices are obtained from calculated logP values, measured affinities and, eventually, 
measures of ligand size. They do not explicitly include thermodynamic quantities but logP that 
characterizes lipophilicity is related to the entropic contribution of apolar desolvation upon ligand-
protein complex formation, the latter correlating with the apolar surface area buried in the complex 
[18] (see above). In this respect, lipophilic indices and enthalpic indices are expected to contain 
overlapping information, the former having the advantage that they can be obtained without 
thermodynamic measurements. Establishing a relationship between efficiency indices and binding 
enthalpy would support enthalpic optimization by easily calculated indices. LLE and binding enthalpy 
was shown to exhibit some association [53] although the relationship observed appear to be system 
specific and semi-quantitative in the majority of the cases studied. Our experience with multiple LLE-
H datasets suggests that the correlation is much improved for congeneric compound series. The 
extent and utility of the relationship between LLE and binding enthalpy merit further studies. 
Table 2 presents ligand property changes of different types of medicinal chemistry optimizations. 
Data for successful fragment optimizations leading to clinical candidates and successful lead 
optimizations leading to marketed drugs are shown together with data of optimizations performed 
under thermodynamic control. It is instructive to see that thermodynamic optimizations are able to 
improve potency with a modest increase in molecular size without notable change in logP and this is 
reflected in an almost constant LELP and an improving LLE. In this way, thermodynamic optimizations 
produce average property changes that resemble to successful optimizations. 
 
Optimization case studies 
 Renin inhibitors 
 
Diaminopyrimidine-type renin inhibitors were discovered by an HTS campaign at Pfizer identifying 1 
having high micromolar affinity (Figure 6) [54].   
Parallel synthesis of a 450-membered focused library around the diaminopyrimidine core resulted in 
2, a low micromolar renin inhibitor. Structural analysis of the renin-2 complex revealed that the large 
S2 hydrophobic pocket and the smaller hydrophobic S3 subpocket were unoccupied. Since 
preliminary studies to fill the S2 pocket failed 2 was first tethered by a tetrahydroisoquinoline (3) and 
a benzoxazinone (4) ring system which were extended by a methoxypropyl side-chain toward the S3 
subpocket [54,55]. Both compounds showed substantially higher affinity relative to 2 with a 
particular advantage of 3 having lower IC50 and Kd as compared to that of 4. Ligand efficiency was 
improved similarly in both cases (Supplementary Table S1), however the improvement was more 
significant in SILE than LE that is the direct consequence of size dependency.  Comparing lipophilic 
efficiency values, however, indicated a large difference between 3 and 4. Since the benzoxazinone (4) 
is much less lipophilic than the tetrahydroisoquinoline (3) both LLE (larger is better) and LELP (smaller 
is better) showed preference for 4. In fact, 4 is located in the most preferred region of the LLE-LELP 
plot (Supplementary Figure S3) characterized by oral drugs and compounds having sufficiently good 
human pharmacokinetic profile to enter into phase 2 trials [56]. 
Thermodynamic profiles of 3 and 4 were recorded and were compared to that of their predecessor 2 
(Figure 7). While optimization from 2 to 3 was mainly due to entropic improvements conversion of 2 
to 4 is an enthalpically driven process. Analysis of the X-ray structure of the renin-3 complex revealed 
that the methoxypropyl sidechain reached the S3 subpocket.  Since the displacement of ordered 
water molecules from the hydrophobic S3 subpocket was entropically favored it compensated for the 
entropy loss associated with the decreased flexibility of the side chain. These significant entropy 
effects identify the optimization of 2 to 3 as being basically entropically driven as indicated by the 
decreasing EE and the marginal improvement detected in SIHE (Supplementary Table S1). Although 
the X-ray structure of the renin-4 complex is not publicly available, the complex of its 2,2-dimethyl-
benzoxazinone analog was crystallized and showed that in addition to filling the S3 subpocket the 
benzoxazinone group was involved in new polar contacts within the active site and its methyl group 
in position 2 formed favored van der Waals contacts. These new interactions yielded a significant 
gain in enthalpy (H~4 kcal/mol) that was only partially compensated by the entropic penalty (TS~2 
kcal/mol) due to the decreased flexibility and desolvation entropy. The significant enthalpy effects 
detected make this optimization enthalpy driven that is indicated by the much improved EE and SIHE 
(Supplementary Table S1). Although the enthalpically optimized compound (4) is somewhat less 
potent than that obtained by entropically driven optimization (3) its size and lipophilic efficiency are 
superior. This rationalizes that optimized compounds reported from the diaminopyrimidine 
chemotype typically contain benzoxazinone rather than tetrahydroisoquinoline rings [57]. Further 
optimization of 4 was focused on the central region and the S3 subpocket. Introducing the lipophilic 
difluorophenyl moiety into position 2 of the benzoxazinone ring resulted in 5 with improved potency 
(IC50) but interestingly kept the affinity (Kd) virtually constant. Although LE does not change too much 
and SILE improved a bit a large drop in LLE and LELP was detected (Supplementary Table S1). The 
thermodynamic analysis confirmed this step entropically driven with significant reward in binding 
entropy connected with remarkable enthalpy loss (Figure 7a). Figure 7b summarizes the 
thermodynamics of the optimization path. Although the last step from 4 to 5 was entropically driven 
the large enthalpic step from 2 to 4 makes compound 5 more enthalpic (c.f. the H axis) and more 
potent (c.f. G axis)  than 3 indicating 5 as a better lead. Further optimization of the S3 sidechain of 5 
finally led to compound 6 having somewhat less affinity but improved ADME properties. 6 showed 
good bioavailability both in rat (74%) and dog (19%) triggering its selection for preclinical 
development as identified from the Integrity database [57].  
    
 Tankyrase inhibitors 
 
A Novartis team described a series of tankyrase TNKS1/TNKS2 inhibitors inhibiting Wnt pathway 
signaling. This set of compounds is exemplified by XAV939 (7) having low nanomolar affinity towards 
both TNKS isoforms (Figure 8) [58,59]. Compound 7, however, showed moderate selectivity towards 
other PARPs, particularly against PARP2 and had moderate metabolic stability that limited its in vivo 
application. In addition, thermodynamic profiling of 7 revealed that despite of the favourable 
enthalpic contributions the compound binds entropically to TNKS2 (Figure 9a). The Novartis team 
therefore started an optimization program from 7 that aimed the improvement of potency, 
selectivity, solubility and metabolic stability [60]. Since 7 is structurally similar to many PARP 
inhibitors they introduced a number of modifications to the bicyclic core of 7 from which the 
dihydropyran analogue (8) was somewhat less potent but significantly more polar (Figure 8).  
Decreased lipophilicity of 8 resulted in better solubility and increased metabolic stability while 
maintaining LLE and improving LELP (Supplementary Table S2). In agreement with these 
improvements the thermodynamic profile of 8 showed that the compounds bind enthalpically 
(Figure 9a) as reflected in improved EE and SIHE values (Supplementary Table S2). One of the major 
advantages of 8, however, was the improved selectivity over PARP1 and 2 that prompted the team to 
investigate its analogues further. X-ray analysis of 7 confirmed that the core occupies the 
nicotinamide and diphosphate pockets. In replacing the trifluoromethyl group by a number of 
aromatic substituents with different polarity, it turned out that this part of the molecule has no 
direct interactions with the protein but instead the substituents are exposed to the bulk solvent.  
Based on this observation the team suggested introducing amphipathic groups that on one hand 
might form hydrophobic interactions with the target and on the other hand fine-tune the lipophilicity 
of the compounds. To achieve this goal the trifluoromethylphenyl substituent of the dihydropyran 
core was replaced by the phenylethyl-carboxamido sidechain of a moderately active screening hit 
resulting 9 (Figure 8).  
X-ray crystallography of the screening hit complexed with TNKS1 revealed that the compound binds 
to the NAD+ donor site and its sidechain, particularly the thiophene moiety forms van der Waals 
interactions with the hydrophobic nook. Compound 9 unifies the advantageous contribution of the 
dihydropyran core with the beneficial effect of the sidechain on potency. Although ligand efficiency 
indices were getting worse a bit comparing the thermodynamic profile of 9 to its predecessor (8) 
shows a significant improvement in binding enthalpy (Figure 9a) as indicated by the much improved 
EE and SIHE values (Supplementary Table S2). The enthalpic reward realized in 9 is likely the effect of 
a new hydrogen bond formed with the amide carbonyl and also the van der Waals contacts of the 
thiophene moiety.  As a result the team identified a promising enthalpic lead having good selectivity 
profile but moderate potency and still low metabolic stability.  
Further optimization of 9 therefore involved the variation of the metabolically vulnerable thiophene 
and phenethyl moieties. This activity was facilitated by the identification of a screening hit that binds 
not only in the nicotinamide pocket but reaches the adenosine site as well. X-ray analysis of its TNKS1 
complex revealed that the (fluorophenylpiperidinyl)methanone sidechain of the hit forms 
advantageous van der Waals interactions with the groove in the adenosine pocket that suggested 
replacing the sidechain of 9 with that of the hit. In fact, compound 10 designed on this basis showed 
high potency, good selectivity and much improved metabolic stability (Figure 8). The introduction of 
the more polar side chain made the compound less lipophilic that together with the increase in 
potency resulted in improved ligand efficiency values. Although LE did not change too much there 
was some improvement in SILE and more importantly both LLE and LELP were getting significantly 
better (Supplementary Table S2). It is important to note that all of these improvements were 
achieved with keeping the enthalpic character of compound virtually unchanged (Figure 9a) and 10 
represents the first TNKS inhibitor forming interactions simultaneously with the nicotinamide, 
adenosine and nook pockets of the enzyme.  
In the last step of the optimization the metabolically vulnerable thiophene moiety of 10 was changed 
to a cyclopropylmethyl group (Figure 8, 11) that did not influence the potency significantly and kept 
ligand efficiency constant (Supplementary Table S2), however, improved the oral exposure of the 
compound ten-fold.  The introduction of the apolar cyclopropyl substituent increased logP/logD as 
reflected in slightly worse lipophilic efficiency indices (Supplementary Table S2, LLE and LELP). In 
agreement with these changes the thermodynamic profile of 10 became more entropic (Figure 9a), 
but still predominantly enthalpically driven. The somewhat decreased EE and SIHE values 
(Supplementary Table S2) indicate this change in binding thermodynamics that can be attributed to 
the desolvation of the hydrophobic cylopropylmethyl moiety. Finally, improving lipophilic efficiency 
further, the fluorophenyl group of 11 was changed to methoxyphenyl that resulted in 12 (Figure 8, 
TNKS656) with improved LLE and LELP values while maintaining the ligand efficiency (LE, SILE). 
Comparing the thermodynamic profile of 12 to 11, a slight improvement in the binding enthalpy was 
detected that is reflected in the improved enthalpic efficiency (EE, SIHE) of the compound 
(Supplementary Table S2). 12 was then subjected to extensive in vivo characterization, showed good 
exposure and moderate bioavailability and more importantly was found to be effective on 
adenocarcinomas obtained from a transgenic mouse model with Wnt signaling activation.  
Summarizing the optimization process we depicted the compounds 7-12 on the G-H graph (Figure 
9b). The optimization process has been started from the entropic binder 7 that was converted to a 
compound with strong enthalpy driven binding in two steps (from 7 to 8 and 8 to 9). Adjustment of 
physicochemical and ADMET properties involved only small changes in the thermodynamic profile 
(relative to 9) that were both entropic and enthalpic and resulted in compound 12 with a significant 
enthalpic character. It is important to note that in agreement to our observation [14] significant 
improvement in binding enthalpy was achieved in the early phase of the optimization with less 
complex compounds. Furthermore, the Novartis tankyrase dataset with PARP1 and PARP2 selectivity 
data supports the hypothesis that enthalpic compounds are generally more selective [11]. Although 
the thermodynamic profiles of key compounds were recorded the authors used lipophilic efficiency, 
particularly LLE as the major design tool in this optimization. The LLE-LELP plot (Supplementary 
Figure S4) provides a straightforward validation for this approach since all the compounds except for 
9 are located in the most preferred region identified by marketed drugs and Phase 2 compounds. 
 
 
 Matrix metalloprotease 12 (MMP12) inhibitors 
 
Matrix metalloproteinases are zinc containing proteases having numerous high affinity inhibitors that 
mostly bind to the substrate binding groove forming interactions with the Zn-site and also in the 
hydrophobic S1’ pocket. Bertini and coworkers investigated the binding thermodynamics of a 
number of N-hydroxy-2-(phenylsulfonamido)acetamides (Figure 10) [61] and analyzed their 
thermodynamic profiles in relation to their binding mode. This type of inhibitors can be derived from 
acetohydroxamic acid (13, AHA), a fragment that chelates the Zn ion directly. Although this fragment 
has moderate affinity in the low millimolar range it showed excellent ligand efficiency and lipophilic 
efficiency (Supplementary Table S3). Isothermal titration calorimetry experiments revealed 13 an 
enthalpic binder that might serve as a suitable starting point for optimization. Linking the 
phenylsulfonamide fragment that binds in the S1’ cavity [62] and 13 resulted 14 with significantly 
improved affinity. This key step of optimization improves both ligand efficiency (LE and SILE but to a 
different extent) and lipophilic efficiency values significantly (Supplementary Table S3). From a 
thermodynamic point of view fragment linking was associated with a large improvement in binding 
enthalpy (Figure 11). Enthalpic efficiency changed accordingly, however, the improvement in SIHE 
was more pronounced relative to changes in EE. This effect, together with the similar situation found 
for LE and SILE, underlines the importance of size independent metrics when comparing ligands with 
largely different size.   
Further optimization of 14 was first realized by introducing different substituents to the para position 
of the benzenesulfonamide ring. The authors investigated the 4-F (15), the 4-methoxy (16) and the 4-
phenyl (17) analogues.  Introduction of the fluorine substituent did not improve the potency, on the 
other hand the binding affinity of both 16 and 17 was improved.  Analysis of the corresponding X-ray 
structures revealed that the substituted phenyl group fits into the S1’ pocket. The methoxy 
derivatives penetrate somewhat deeper into the S1 pocket as compared to the unsubstituted 
derivative. This suggests that the methoxy group probably displaces water molecules from the 
hydrophobic S1’ pocket that would result in some gain in binding entropy. Although the methoxy 
group forms van der Waals contacts it also disturbs the optimal H-bond interactions of the 
sulfonamide group and the coordination of the hydroxamic acid. The fluoro substituent introduces 
less perturbation, while the second phenyl group of 17 represents a new site for hydrophobic 
interactions but more importantly decreases the hydrophobic interactions of the 
benzenesulfonamide ring within the S1’ pocket. Thermodynamic profiles are in accordance with 
these structural changes (Figure 11a). The largest entropic reward was observed for 15, however, the 
binding of the compound is still enthalpically driven. The introduction of the methoxy substituent 
improved the binding enthalpy further and therefore this transformation is considered as 
enthalpically driven optimization. The second phenyl group in 17 provides entropic reward due to 
improved desolvation that makes this optimization step being entropically driven.  In summary, from 
the thermodynamic point of view the most enthalpic methoxy derivative (16) can be considered as 
the preferred starting point for further optimization. Interestingly, enthalpic efficiency indices did not 
discriminate effectively this subset of compounds (Supplementary Table S3).  Analyzing ligand 
efficiency indices LE and SILE prefer 15 and 16 over 17 and a similar trend was observed for both LLE 
and LELP. This information together with enthalpic efficiency indices suggests selecting 16 for further 
optimization. 
 In the next round the authors introduced substituents to the sulfonamide nitrogen and the carbon 
atom of the acetamido moiety. The sulfonamide nitrogen was substituted by isobutyl (18), 2-
hydroxyethyl (19) and 2,3-dihydroxypropyl (20) groups while C-substituents involved hydroxymethyl 
(21) and 2-hydroxyethyl (22) groups in D configuration. Introduction of the hydrophobic isobutyl 
group increased the affinity of 18. Ligand efficiency (LE) was slightly decreased, however, SILE 
improved a bit (Supplementary Table S3). The enthalpic efficiency (SIHE) remains virtually constant, 
but LELP was getting worse due to the increased lipophilicity. The thermodynamic profile of 18 is in 
line with these findings. Improvement of the binding affinity has been achieved by entropically driven 
optimization as indicated by the beneficial change in binding entropy (Figure 11a). In contrast, 
introducing the polar hydroxyethyl group (19) kept the ligand efficiency (SILE) constant and improved 
the enthalpic efficiency (SIHE) to some extent. The observed reward in binding enthalpy could be 
attributed to van der Waals contacts formed between the ethyl spacer and Pro238. More 
importantly, the terminal hydroxyl group forms H-bonds with a number of water molecules located 
at the entrance of the substrate binding site. The polar character of the substituent helped control 
the lipophilicity and improved the LLE value. Similar trends were observed for the LLE of the 2,3-
dihydroxypropyl (20) analogue that improved further due to the more polar character of 20 relative 
to 16. Binding of 20 was found to be enthalpically driven, however, contrary to 19 here the binding 
entropy was also improved marginally. C-substituted analogues (21 and 22) were found to be almost 
equipotent to N-substituted compounds. Contrary to latter ligands improvements in the affinity of 21 
and 22 was due to entropic rewards. Considering similar changes in ligand efficiency parameters 
observed for both N- and C-substituted analogues the most enthalpic analogue (19) having also the 
highest SIHE is suggested for further studies. 
The optimization path has been summarized on the G-H graph (Figure 11b). The optimization 
process was started from the enthalpic fragment binder 13 that was converted to a compound with 
strong enthalpically driven binding (14). Optimization of the aromatic substituent was entropically 
driven, here we can select the compound with maximal binding enthalpy (16). Finally, from the 
comparative thermodynamic profiling of N- and C-substituted analogues (18-22) the most enthalpic 
compound (19) was achieved by enthalpically driven optimization.  Again, in agreement to our 
observation [14] significant improvement in binding enthalpy was achieved in the early phase of the 
optimization with less complex compounds that in this particular case was realized by linking two 
fragments. 
 
 Heat shock protein 90 (HSP90) inhibitors 
 
Recently Astex reported  that combined fragment screening using both NMR and X-ray 
crystallography against HSP90 yielded a new aminopyrimidine starting point (Figure 12) with high 
micromolar affinity (23) [63]. The initial fragment hit showed reasonable ligand efficiency and also 
acceptable lipophilic efficiency (Supplementary Table S4). X-ray analysis of the HSP90-23 complex 
revealed that the fragment is located in a deep pocket forming hydrogen bonds with Asp93 and four 
water molecules. The binding mode of the aminopyrimidine ring resembled to that of the adenosine 
ring of ADP having two small hydrophobic pockets in close proximity. Since 23 was twisted around 
the bond connecting the pyridine and the aminopyrimidine ring this conformation was maintained by 
introducing an ortho methoxy group when replacing the original pyridine ring to benzene. 
Introducing a methyl group to the 2-position of the aminopyrimidine ring yielded 24 with increased 
potency and improved ligand efficiency (both LE and SILE) while lipophilic efficiency was kept on a 
reasonable level (Table 5). Next there are two options to improve the affinity of the fragment further. 
In one case a chlorine atom was introduced to the ortho position of the 2-methoxyphenyl ring (25) 
that was replaced by another methoxy group resulting the dimethoxyphenyl analogue (26). The 
other option replaces the methyl group of the aminopyrimidine ring by a chlorine (27) and the 
introduction of the second methoxy group yields the chloro analogue (28) of 26. Comparing ligand 
efficiencies compounds on the second path are more beneficial in terms of both LE and SILE and also 
the lipophilic efficiencies are better for 27 and 28 relative to 25 and 26 (Supplementary Table S4). On 
the first path the introduction of the 2-chloro substituent to the phenyl ring was associated with a 
significant reward in the binding enthalpy (Figure 13), however the conversion of 25 to 26 was 
coupled to a large entropic reward. Following the other path the methyl to chloro replacement from 
24 to 27 is enthalpically driven. It is appealing to speculate that the enthalpy gain observed in 
replacing Me by Cl is owing to the halogen bond that can be clearly identified in the corresponding X-
ray structure [63]. Similar to the first path the introduction of the second methoxy group to the 
phenyl ring (from 27 to 28) is entropically driven. Considering the overall change in binding enthalpy 
and entropy along the path from 24 to 26 and 28 it seems that 28 is more enthalpic than 26 that 
makes the former more suitable for further optimization. In fact, the optimized derivatives reported 
from these laboratories contain chloro rather than methyl substituent on the aminopyrimidine core. 
 
Future perspective 
The recognized relation between binding thermodynamics and the physicochemical and druglike 
properties of ligands ensures that the measurement and analysis of binding thermodynamic profiles 
remain valuable tools in drug discovery projects. The predominant experimental technic for 
measuring thermodynamic profiles is expected to remain isothermal titration calorimetry as it is able 
to provide G, H, and S in a single experiment for soluble proteins. The limitations of ITC 
measurements, namely throughput and the amount of protein required have been significantly 
alleviated by recent technological developments [65,35] and this is likely to increase the role of 
thermodynamic measurements both in hit identification and in optimization. This trend is expected 
to apply also for fragment based drug discovery since recent results have clearly demonstrated the 
feasibility of applying ITC in this domain [32,34,35]. 
Binding thermodynamics and structural analysis, most often by X-ray crystallography, are typically 
applied together in an attempt to rationalize binding thermodynamics by structural features. 
Although some trends on how ligand and protein structures affect binding thermodynamic profiles 
have been set up, we are currently unable to rationally design binding thermodynamics and even the 
interpretation of thermodynamics profile is often challenging. The interplay of diverse events among 
them the breaking and formation of polar and van der Waals interactions, solvent structural changes 
and the alteration of the available configuration space for the system results in the observed 
thermodynamic profile and further data are to be accumulated and analyzed in order to better 
understand the subtle events that contribute to binding thermodynamics. Thermodynamic and 
structural studies are expected to be jointly applied also in the future since they are both required to 
provide detailed information on the nature and quality of interactions and on the changes upon 
complex formation. 
Our current knowledge on the relation between structural features and binding thermodynamic 
profiles refer to ligand-protein complexes in general. More research are needed to clarify whether 
various protein families behave differently, whether soluble and membrane proteins exhibit distinct 
binding thermodynamics and whether other drug targets like DNAs have different binding 
thermodynamic characteristics. 
Binding kinetics is also in the forefront of the current interest in drug discovery [64] owing to its 
influence on drug pharmacology via the residence time of the drug-target complex. Since binding 
kinetics studies kon and koff, the association and dissociation rate constants that also determine 
binding thermodynamics the two fields will mutually profit from the continuing interaction. 
 
 
Executive summary 
 Binding thermodynamics together with structural information are able to characterize the 
quality of interactions in ligand-protein complexes. 
 Affinity improvement achieved by the introduction of apolar groups or by increased rigidity 
typically increases the entropic contribution of binding free energy and tends to deteriorate 
physicochemical and pharmacokinetic profiles by size and lipophilicity increase. 
 The introduction of polar groups into the ligands so that they form favorable interactions 
with the protein leads to dominantly enthalpic gain in the binding free energy and allows a better 
control of molecular size and lipophilicity. 
 Favorable polar interactions are restricted to a narrow range of the geometrical arrangement 
of the interacting atoms and this makes the rational design of enthalpic optimization challenging. 
 Binding thermodynamic profiles exhibit ligand size dependent trends; Small ligands, like 
fragments, typically bind with favorable enthalpy owing to their small size and polarity, while the 
entropic contribution to binding gains importance with increasing ligand size and increasing affinity. 
 The control of the binding thermodynamic profile is beneficial to the physicochemical and 
druglike properties of drug candidates and such a control is more viable in the early phases of 
optimizations. 
 When thermodynamic and structural data are not accessible then efficiency indices can 
provide similar information on interactions quality. Ligand efficiency and lipophilic efficiency indices 
are typically easily available and they are able to contribute to balanced optimizations particularly in 
the early phases. 
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key words/technical terms/concepts  
 
ADMET PROPERTIES 
Absorption, distribution, metabolism, excretion and toxicological properties 
 
THERMODYNAMIC PROFILE 
The balance between enthalpic and entropic contributions to binding free energy 
 
ENTHALPY-ENTROPY COMPENSATION 
In the context of binding thermodynamics enthalpy-entropy compensation refers to the observation 
that structural changes of either of the ligand or the protein typically lead to significant changes in 
both enthalpy and entropy but these changes are largely compensating and result in a smaller 
change in binding free energy. 
 Table 1 Definitions of efficiency indices  
Definition Reference 
LE=G/HA.37pIC50/HApIC50/HA 41 
BEI= pIC50/MW 42 
SILE=pIC50/HA
0.3 or pKi/HA
0.3 43 
LLE= pIC50 – logP 21 
LELP=logP/LE 1 
LLEAT=0.111 + 1.37(LLE/HA) 52 
EE=H/HAor H/HApol 45 
SIHE=H/(2.303RT)/40*HA0.3 14 
Table 2 Changes in various molecular properties and efficiency indices in different type of medicinal 
chemistry optimizations 
Process 
Ref 
N 
pPot 
change 
MW 
change 
logP 
change 
LE 
change 
SILE 
change 
LLE 
change 
LELP 
change 
Fragment 
successful 
44 
14 3.05 168.1 0.7 -0.02 0.84 2.6 1.5 
Lead opt. 
successful 
Error! 
Reference 
source 
not 
found. 
60 2.08 89.9 0.05 0.01 0.85 2.1 -1.1 
Thermo 
opt. 
a 
30 1.27 63.8 0.01 0.01 0.37 1.22 0.09 
 
a Calculated from data in Supplementary Table S5 
Figure captions 
Figure 1 Apolar surface area (ASA, left vertical axis)) and the estimated binding free-energy 
contribution (right vertical axis) versus the number of heavy atoms (HA) (see text for details). Straight 
line indicates maximal surfaces and free-energies. Adapted from ref 17. Copyright (2012) American 
Chemical Society. 
Figure 2 Average enthalpic (pKH) and entropic (pKS) contributions to binding versus heavy atom count 
(HA). Standard errors are shown by vertical bars. Data points represent 757 ligand protein complexes 
[14]. 
Figure 3 pKd of the highest affinity compounds and pKH of the most enthalpic high affinity compounds 
versus the number of heavy atoms (HA) (see text for further details). Standard errors are shown by 
vertical bars. Data points represent 757 ligand protein complexes [14].  
Figure 4 Average enthalpic (pKH) and entropic (pKS) contributions to binding versus affinity (pKd). 
Standard errors are shown by vertical bars. Data points represent 757 ligand protein complexes [14]. 
Figure 5 Enthalpic and entropic components of binding for 284 fragment-protein complexes [14]. The 
contours represent density of points. 
Figure 6 Optimization of diaminopyrimidine-type renin inhibitors 
Figure 7 a) Thermodynamic profile of renin inhibitors. b) Thermodynamics of the optimization path of 
renin inhibitors  
Figure 8 Optimization of tankyrase inhibitors 
Figure 9 a) Thermodynamic profile of tankyrase inhibitors. b) Thermodynamics of the optimization 
path of tankyrase inhibitors 
Figure 10 Optimization of MMP12 inhibitors 
Figure 11 a) Thermodynamic profile of MMP12 inhibitors b) Thermodynamics of the optimization 
path of MMP12 inhibitors 
Figure 12 Optimization of aminopyrimidine-type HSP90 inhibitors 
Figure 13 Thermodynamic profile of HSP90 inhibitors
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Box 1 
BINDING THERMODYNAMICS 
The improvement of ligand affinity is equivalent with 
the decrease of the ligand binding free-energy (Gbind) 
corresponding to the ligand-protein binding process 
 
 
Gbind relates to the dissociation constant  , 
often expressed as  via the equation 
 
Using the above equations one can write [14] 
 
with  and . The use of pKH 
and pKS instead of H and TS has the advantage that 
their higher values correspond to more favorable 
contributions and their sum gives pKd, a quantity 
generally used for characterizing ligand affinity. 
 
